Taken 1m shares in #HZM over past 3 days, av. 3.96p – £57.3m mkt cap. Current net cash position of ~£29m, 50% of cap.
Two 100% owned Nickel pre-production assets in Brazil:
Araguaia - construction ready, sourcing development capex.
Vermelho - PFS just completed, DFS next.
#HZM Araguaia: at $16.4k Ni, project has a post tax NPV of $1.2bn, v development capex of $443m. 2.7x is a very heathy ratio – IRR comes in at 30.7%.
Co has secured a 2.25% royalty deal with mining financier, Orion, for $25m cash. Orion will likely provide further devel. capex.
#HZM Vermelho: at $16.4k Ni, project has a post tax NPV of $1.7bn, v development capex of $652m. Again, very healthy. IRR of 26.3%.
Whilst Araguaia is a FeNi deposit, Vermelho is NiCo – i.e. geared towards providing for a major macro trend, the electric vehicle revolution.
#HZM wants to develop Araguaia on its own, reaching 29ktpa output in five years. It's currently in talks with project financiers (investors and debt providers alike).
For Vermelho, it sounds like a partner will be brought on board at project level to fund the DFS.
For me, the market has paid too much attention to the drop in Ni over the past 7 weeks, from a peak of $18.7k to $16.1k this week.
Ni rocketed by over 50% from end June to start Sept. It was always going to cool off.
It's back up to $16.8k already and in a clear uptrend.
#HZM valuation: Orion’s royalty agreement implies a valuation for Araguaia alone of ~10p. Personally I think it should be on a 15% to 20% of Stage 1 post tax NPV ($691m) at present, which implies a range (at $16.4k Ni) of 7.2p to 9.6p.
#HZM valuation: Vermelho should command a valuation of 5% to 7% of project NPV at this post PFS stage, given its strategic importance – on a global scale – to the EV revolution. That implies a range of 6.0p to 8.3p.
My base case for #HZM right now is thus 13.2p. Bull case 17.9p.
However, it should be noted that it is almost universally agreed that Ni is going to push up much higher in the next few years.
At $20k Ni, the combined NPV of the two projects (fully developed) would be $4.3bn.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6